文献速递膀胱癌与上尿路尿路上皮癌

在美国人群中预测非肌层浸润性膀胱癌的复发与进展

Predicting Nonmuscle Invasive Bladder Cancer Recurrence and Progression in a United States Population.
PubMed 文献 · J Urol · 2017-04-19

本研究在美国多中心人群中回顾性分析1333例非肌层浸润性膀胱癌患者,中位随访37个月,比较EORTC、CUETO模型与美国NCCN指南治疗分组的预测区分度。5年复发c指数EORTC为0.59、CUETO为0.56,进展c指数分别为0.74和0.72,NCCN分别为0.56和0.75。作者认为NCCN指南是简便可选方案,其预测能力与EORTC和CUETO模型相当。

要点

  • EORTC与CUETO的5年复发c指数分别为0.59和0.56,进展c指数分别为0.74和0.72。
  • NCCN指南4个治疗分组的5年复发与进展c指数分别为0.56和0.75。
  • 接受卡介苗(BCG)治疗的患者中,3种风险模型的区分度均下降。

核心结论

  • 作者认为需要改进非肌层浸润性膀胱癌的预测工具;在新工具出现前,NCCN指南对临床医生是简便选项,其预测能力与EORTC和CUETO模型相当。

研究设计与样本

  • 在美国多中心人群中回顾性分析非肌层浸润性膀胱癌患者的电子病历,共纳入1333例,中位随访37个月。
  • 按EORTC与CUETO评估无复发生存与无进展生存,并用1年和5年c指数评价区分度。
  • 将EORTC与CUETO的区分度与NCCN指南所述4个非肌层浸润性膀胱癌治疗分组的区分度进行比较。

主要发现

  • 5年时EORTC与CUETO的复发c指数分别为0.59和0.56,进展c指数分别为0.74和0.72。
  • NCCN指南的5年复发与进展c指数分别为0.56和0.75,与EORTC和CUETO相似。
  • 接受卡介苗治疗的患者中,3种风险模型的区分度均下降。
  • EORTC更能识别复发或进展低风险患者,但高估了高风险患者的5年进展风险。

关键数值与推荐

  • 5年复发c指数:EORTC 0.59,CUETO 0.56,NCCN 0.56。
  • 5年进展c指数:EORTC 0.74,CUETO 0.72,NCCN 0.75。
  • NCCN指南描述了4个非肌层浸润性膀胱癌治疗分组。

临床怎么用

  • 作者认为在新预测工具开发出来之前,NCCN指南是治疗非肌层浸润性膀胱癌临床医生的简便选项,其预测能力与EORTC和CUETO模型相当。

局限性

  • 本研究受回顾性设计限制。
  • 作者指出需要改进的预测工具。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We assessed the performance of the EORTC (European Organisation for Research and Treatment of Cancer) and CUETO (Club Urológico Español de Tratamiento Oncológico) nonmuscle invasive bladder cancer predictive models compared to current United States NCCN Guidelines® in an American population. MATERIALS AND METHODS: We retrospectively analyzed the electronic medical records of patients with nonmuscle invasive bladder cancer in a multicenter population in the United States. We evaluated recurrence-free and progression-free survival according to EORTC and CUETO, and assessed discriminative performance with the c-index at 1 and 5 years. We then compared the discrimination of EORTC and CUETO to the discrimination of the 4 nonmuscle invasive bladder cancer treatment groups described in NCCN Guidelines. RESULTS: We identified 1,333 patients with nonmuscle invasive bladder cancer and a median followup of 37 months. At 5 years the recurrence c-index of EORTC and CUETO was 0.59 and 0.56 while for progression it was higher at 0.74 and 0.72, respectively. NCCN Guidelines demonstrated a similar c-index of 0.56 and 0.75, respectively. The discrimination of all 3 risk models decreased in patients who received bacillus Calmette-Guérin. EORTC was better able to identify patients at low risk for recurrence or progression but it overestimated the 5-year risk of progression in patients at high risk. This study was limited by its retrospective design. CONCLUSIONS: Our work illustrates the need for improved predictive tools for clinicians who treat patients with nonmuscle invasive bladder cancer. However, until new tools are developed NCCN Guidelines are a simple option for clinicians who treat patients with nonmuscle invasive bladder cancer. Those guidelines provide predictive power comparable to that of the EORTC and CUETO models.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Ravvaz K, Walz ME, Weissert JA, et al. Predicting Nonmuscle Invasive Bladder Cancer Recurrence and Progression in a United States Population. J Urol. 2017. PMID: 28433642. doi:10.1016/j.juro.2017.04.077

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。